BASKING RIDGE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will provide a corporate overview in a pre-recorded, on-demand presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The confe ...

Core Viewpoint - Lisata Therapeutics, Inc. is set to report its financial results for Q2 2025 on August 7, 2025, and will host a conference call to discuss these results [1]. Group 1: Financial Reporting - The financial results for the second quarter ended June 30, 2025, will be announced after the close of trading on August 7, 2025 [1]. - A conference call will be held at 4:30 p.m. Eastern time on the same day to discuss the financial results [1]. Group 2: Conference Call Participation - Interested participants must register for the conference call via a provided link and will receive an email with dial-in options [2]. - Participants are encouraged to join the call 15 minutes early to avoid delays [2]. Group 3: Webcast Availability - A live webcast of the conference call will be available on Lisata's website and can be replayed for 12 months starting two hours after the call concludes [3]. Group 4: Company Overview - Lisata Therapeutics is focused on developing innovative therapies for advanced solid tumors and other serious diseases [4]. - The company's investigational drug, certepetide, aims to enhance the targeting and penetration of anti-cancer drugs in solid tumors [4]. - Lisata has established significant commercial and R&D partnerships based on its CendR Platform technology and anticipates announcing multiple milestones in the next 1.5 years [4]. - The company expects its capital to fund operations into Q4 2026, covering anticipated data milestones from ongoing and planned clinical trials [4].